이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE)

2022년 7월 27일 업데이트: Dr Rahul Ladwa, Queensland Health

A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab - DESQUAMATE

Cutaneous Squamous Cell Carcinoma (cSCC) is typically associated with a high tumour mutation burden, with the majority caused by Ultraviolet (UV) exposure (Pickering et al., 2014).

The use of this trial using neoadjuvant Pembrolizumab in patients with cSCC who will otherwise undergo highly morbid radical surgical resection has multiple potential advantages, including:

  1. Reduction in surgical and radiotherapy morbidity by reducing tumour burden and allowing the appropriate selection of patients to undergo post-operative radiotherapy;
  2. Provision of immediate information about pathological response and
  3. Access to tissue to provide insight into resistance mechanisms and identification of biomarkers of response.

The Investigators hypothesized that the use of neoadjuvant Pembrolizumab could reduce tumour burden allowing appropriate selection of patients undergoing radical surgical resection and adjuvant radiotherapy.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (예상)

27

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

  • 호주
    • New South Wales
      • Camperdown, New South Wales, 호주, 2050
    • Queensland
      • Herston, Queensland, 호주, 4029
      • Woolloongabba, Queensland, 호주, 4102

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Histologically confirmed diagnosis of invasive cSCC that is locally advanced (Stage II-IV on AJCC 8th edition) assessed preoperatively as sufficiently high risk that they will warrant post-operatively RT (as recommended by MDT) who is a candidate for a complete resection.

Note: Participants with tumors arising on cutaneous non-glabrous (hair-bearing) lip with extension onto vermillion (dry red lip) may be eligible after communication and approval from the principal investigator. Participants for whom the primary site is the nose may be eligible after communication and approval from the MDT if the primary site is skin, not nasal mucosa with outward extension to skin. Participants who have squamous cell parotid metastases and have been treated previously for cSCC are permitted. cSCC that has recurred in the same location after 2 or more surgical procedures are not eligible.

  • Participants must have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days prior to the start of treatment.
  • Participants must have adequate organ function
  • Participants must have a tissue sample adequate for translational research. This tissue sample may be obtained from either a newly obtained core or excisional biopsy.
  • Participants must have a life expectancy of greater than 6 months.
  • Be at least 18 years of age on the day of signing the informed consent. 8. Female participants: Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of trial medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

Note: In the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for the participant to start receiving study medication.

- A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) as defined in Appendix 1 OR A WOCBP who agrees to use an adequate method of contraception during the treatment period and for at least 120 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.

- The participant (or legally acceptable representative if applicable) must be willing and able to provide written informed consent for the trial. The participant may also provide consent for Future Biomedical Research. However the participant may participate in the main trial without participating in Future Biomedical Research.

Exclusion Criteria:

  • Participant has metastatic/unresectable cSCC that cannot be potentially cured with surgical resection, radiotherapy, or with a combination of surgery and radiotherapy.
  • Participant has any other histologic type of skin cancer other than invasive squamous cell carcinoma as the primary disease under study, eg, basal cell carcinoma that has not been definitively treated with surgery or radiation, Bowen's disease, merkel cell carcinoma, melanoma.
  • Participants with any prior allogeneic solid organ or hematopoietic stem cell transplantations are excluded.
  • Participant has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
  • Participant has received prior systemic anti-cancer therapy including investigational agents for cSCC.
  • Participant has received prior radiotherapy to the target lesion.
  • Participant has received a live vaccine within 30 days prior to the first dose of trial drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed-virus vaccines and are allowed; however, intranasal influenza vaccines(eg, FluMist®) are live- attenuated vaccines and are not allowed.
  • Participant is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.

Note: Participants who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

  • Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs) or has a diagnosis of immunodeficiency disorders (such as HIV disease or organ transplantation or hematologic malignancies associated with immune suppression).
  • The following are not exclusionary: vitiligo; asthma; type 1 diabetes; hypothyroidism that required only hormone replacement; or psoriasis that does not require systemic treatment.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial drug.
  • Participant has a diagnosis and/or has been treated for additional malignancy within the past 3 years prior to allocation.

Note: Participants with cSCC of the skin that have undergone potentially curative therapy are not excluded if not related to current diagnosis.

Note: Participants with basal cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical cancer or melanoma in situ) that have undergone potentially curative therapy are not excluded.

Note: Participants with low-risk early-stage prostate cancer, defined as below are not excluded: Stage T1c or T2a with a Gleason score 6 and a prostate-specific antigen (PSA) (10 ng/ml) either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to trial allocation.

  • Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (eg, with use of disease-modifying agents, anticoagulants, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  • Participant has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  • Participant has an active infection requiring systemic therapy.
  • Participant has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.

Note: No testing for Hepatitis B or Hepatitis C is required unless mandated by a local health authority.

  • Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Participant has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the trial.
  • Participant is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A

Neoadjuvant Pembrolizumab 4 cycles, 200mg IV Q3W followed by interval restaging:

If restaging imaging positive will have Radical Neck Resection followed by Pembrolizumab 17 cycles, 200mg IV Q3W +/- External Beam Radiotherapy (if >10% viable tumour cells at resection) If restaging imaging negative will have Mapping biopsy. If biopsy positive will proceed to Radical Neck dissection followed by Pembrolizumab 17 cycles 200mg IV, Q3W If biopsy negative will proceed to Pembrolizumab 17 cycles 200mg IV, Q3W
의약품: Pembrolizumab
Delivery of neo-adjuvant Pembrolizumab
다른 이름들:
  • 외부 빔 방사선 치료
  • Radical Neck Dissection

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Assess the rate of pathological response to neo-adjuvant Pembrolizumab
기간: Will be assessed at the end of Cycle 4 (each cycle is 21 days) of Neo-adjuvant Pembrolizumab.

To assess the rate of pathological response of neo-adjuvant Pembrolizumab in patients with locally advanced, resectable cSCC. Response will be measured by reviewing tissue samples taken at either surgical resection or biopsy following 4 cycles of neo-adjuvant Pembrolizumab. A pathological complete response will show no viable tumour cells.

Pathological response will be determined as:

Major Pathological response (less than or equal to 10% viable tumour cells remaining following 4 cycles of Neo-adjuvant Pembrolizumab) Pathological Partial Response (11-50% of viable tumour cells remaining following 4 cycles of neo-Adjuvant Pembrolizumab) Pathological Stable and/or Progressive disease (greater than 50% viable tumour cells following 4 cycles of Neo-adjuvant Pembrolizumab)
Will be assessed at the end of Cycle 4 (each cycle is 21 days) of Neo-adjuvant Pembrolizumab.

2차 결과 측정

결과 측정
측정값 설명
기간
Objective response Rate
기간: Will be assessed at the end of Cycle 4 (each cycle is 21 days) of Neo-adjuvant Pembrolizumab
To estimate objective response rate (ORR) as per investigator assessed RECIST 1.1 criteria
Will be assessed at the end of Cycle 4 (each cycle is 21 days) of Neo-adjuvant Pembrolizumab
Disease free survival
기간: From date of drug allocation until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 48 months
To estimate investigator assessed disease free survival (DFS) per RECIST 1.1 criteria
From date of drug allocation until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 48 months
Overall Survival
기간: From date of drug allocation until the date of death from any cause, whichever came first, assessed up to 48 months
To evaluate the overall survival (OS) of the participants.
From date of drug allocation until the date of death from any cause, whichever came first, assessed up to 48 months
Locoregional Recurrence
기간: From date of drug allocation until the date of first documented locoregional recurrence or date of death from any cause, whichever came first, assessed up to 48 months
Freedom from locoregional recurrence
From date of drug allocation until the date of first documented locoregional recurrence or date of death from any cause, whichever came first, assessed up to 48 months
Distant Recurrence
기간: From date of drug allocation until the date of first documented distant recurrence or date of death from any cause, whichever came first, assessed up to 48 months
Freedom from Distant Recurrence
From date of drug allocation until the date of first documented distant recurrence or date of death from any cause, whichever came first, assessed up to 48 months
Incidence of Treatment Emergent Adverse Events related to Pembrolizumab
기간: From date of study allocation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE Version 5
From date of study allocation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Number of Participants with Positive Surgical margins
기간: At the end of Cycle 4 (cycle length 21 days)
Positive surgical resection margin defined as tumour cells ≤5mm from the surgical margin.
At the end of Cycle 4 (cycle length 21 days)

기타 결과 측정

결과 측정
측정값 설명
기간
Rate of De-escalation of surgery or post-operative radiotherapy following neo-adjuvant pembrolizumab
기간: At the end of 4 cycles of neo-adjuvant pembrolizumab. Each cycle is 21 days.
Change from planned baseline multidisciplinary meeting recommendation. Patient may de-escalate both Post-operative radiotherapy +/- surgery depending on response
At the end of 4 cycles of neo-adjuvant pembrolizumab. Each cycle is 21 days.
Pattern of failure
기간: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years following last administration of study drug (4 years total)
Pattern of failure, assessed using descriptive analysis of percentages of patients in which disease recurrence for the primary endpoint of the study is due to local recurrence, regional recurrence, or distant recurrence
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years following last administration of study drug (4 years total)
Cumulative occurrence of Second Primary Tumours (SPT)
기간: From date of drug allocation until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 48 months
Cumulative occurrence of SPTs for each patient
From date of drug allocation until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 48 months
18F FDG PET/CT complete metabolic response (CMR) rate
기간: Assessed at the end of Cycle 4 (each cycle is 21 days)
absence FDG uptake of target tumour lesion on 18F FDG PET/CT
Assessed at the end of Cycle 4 (each cycle is 21 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Queensland Health

협력자

Merck Sharp & Dohme LLC

수사관

  • 수석 연구원: Rahul Ladwa, MD, Queensland Health

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 6월 28일

기본 완료 (예상)

2025년 6월 1일

연구 완료 (예상)

2027년 6월 1일

연구 등록 날짜

최초 제출

2021년 6월 14일

QC 기준을 충족하는 최초 제출

2021년 8월 23일

처음 게시됨 (실제)

2021년 8월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2022년 8월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2022년 7월 27일

마지막으로 확인됨

2022년 7월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • Ladwa59935

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All individual data collected during trial in summary

IPD 공유 기간

Immediately following publication with no end date

IPD 공유 액세스 기준

Available for sub-study, meta analysis

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Pembrolizumab에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Lithuania

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

구독하다